MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer Identified by Anchored Multiplex PCR and Next-Generation Sequencing

Recurrent MET exon 14 (MET ex14) somatic splice site mutations have been described in 0.6 to 7% of lung non-small cell carcinomas (NSCLC) [1-3]. These mutations result in exon 14 skipping and subsequent MET activation with clinical trials demonstrating promising sensitivity to c-MET inhibitors [3]. These mutations are typically mutually exclusive of other lung adenocarcinoma known oncogenic driver mutations (e.g., EGFR, KRAS, BRAF, ERBB2, ALK, ROS1) but frequently co-occur with MDM2 and CDK4 amplification on chromosome 12q [2]. MET ex14 mutations display diversity with upwards of 126 distinct DNA sequence variants described necessitating comprehensive genomic profiling by clinical laboratories for routine detection of these mutations in patients [2]. Of note, these MET ex14 splice site mutations are not limited to just NSCLC but also have been identified in a small percentage of gliomas and gastro-esophageal carcinomas [2,4].

Anchored multiplex PCR and next-generation sequencing is a novel method adopted by some clinical laboratories to detect somatic fusion events in formalin-fixed paraffin-embedded (FFPE) tumor tissues. Using RNA and DNA based NGS methods, we identified and confirmed a MET ex14 splice site mutation in two tumor tissues from an 82-year-old woman with lung adenocarcinoma. In our laboratory, DNA and RNA is extracted simultaneously from using the Qiagen AllPrep DNA/RNA FFPE Kit on the QIAcube. Next generation sequencing (NGS) is performed on both the RNA and DNA extracted from the FFPE. RNA undergoes reverse transcription to cDNA and is tested for fusions and other mutations associated with 53 genes using the Archer® FusionPlex® Solid Tumor Kit on the Illumina MiSeq chemistry (anchored multiplex PCR) is that it can detect fusions associated with the genes in this kit without prior knowledge of fusion partners or breakpoints by using universal adaptors at one end of the cDNA [5]. Following sequencing, data analysis is performed using Archer Analysis software (v4.0.11); at this point any fusion partner genes or sequence variants can be identified after aligning to the reference genome. DNA is also tested for hotspot mutations in 50 genes using the AmpliSeq v2 kit on the Ion Torrent PGM instrument; analysis is performed using Torrent Suite (v4.0.2) for alignment and variant calling and Golden Helix SVS (v8.3.4) for annotation. Testing our patient’s tumor DNA with the AmpliSeq v2 assay identified two genomic alterations, a TP53 mutation (c.527G>A, p.C176Y) in exon 5 and a MET substitution mutation (c.2942-1G>A) in the splice site acceptor region (3’ region upstream of ex 14; genomic position 116,411,902) of exon 14 (Figure 1a). The MET ex14 mutation was confirmed with the Archer FusionPlex assay and identified as an oncogenic isoform of MET resulting in skipping of exon 14 (Figure 1b). This particular MET mutation has been previously described by Frampton et al. [2].

Patients with MET ex14 skipping mutations are eligible for therapy with c-MET inhibitors and it is important for clinical laboratories to identify this population of patients. Anchored Multiplex PCR offers the ability to detect structural variants in multiple clinically significant genes, including MET ex14 mutations, and can be incorporated by clinical laboratories into the workflow for genotyping tumors. Several clinical trials are currently ongoing for patients with MET ex14 skipping mutations including: a phase
II study in stage IIIb/IV lung adenocarcinoma with tepotinib who failed standard of care treatment (NCT02864992); a phase II study of capmatinib in NSCLC patients who have received prior MET inhibitor therapy (NCT02750215); NCI-MATCH trial has a phase II arm with crizotinib therapy (NCT02465060); a Phase II, i study of savolitinib (HMPL-504) for patients with locally advanced/metastatic MET-mutation-positive pulmonary sarcomatoid carcinomas (NCT02897479); and, a phase I study of Pf-02341066, a c-met/hgfr selective tyrosine kinase inhibitor in patients with advanced cancer (PROFILE 1001) (NCT00585195). Response of MET ex14 skipping mutation positive tumors to c-MET inhibitors and eligibility for several clinical trials makes this exon skipping mutation a clinically actionable mutation with relevance to therapeutic strategy and outcomes.

Acknowledgements

The data presented in this manuscript was supported and generated through CGAT in the Department of Pathology and Laboratory Medicine of the Geisel School of Medicine at Dartmouth, the Dartmouth Hitchcock Medical Center, and the Norris Cotton Cancer Center.
References


